Bibliography
- Moyle G, Gatell J, Perno CF, Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection. AIDS Patient Care STDs 2008;22:459-71
- Steigbigel RT, Cooper DA, Kumar PN, Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-54
- Ramkumar K, Neamati N. Raltegravir: the evidence of its therapeutic value in HIV-1 infection. Core Evid 2010;4:131-47
- Al-Mawsawi LQ, Al-Safi RI, Neamati N. Anti-infectives: clinical progress of HIV-1 integrase inhibitors. Expert Opin Emerg Drugs 2008;13:213-25
- Zolopa A, Mullen M, Berger D, 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, USA, 143LB 2007
- Min S, Song I, Borland J, Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.. Antimicrob Agents Chemother 2010;54:254-8
- Mascolinli M, Kort R. 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: summary of key research and implications for policy and practice - clinical sciences. Int AIDS Soc 2010;13(Suppl 1):S3
- Garvey EP, Johns BA, Gartland MJ, The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother 2008;52:901-8
- Kobayashi M, Yoshinaga T, Seki T, In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011;55:813-21
- Garrido C, Soriano V, Geretti AM, Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients – Impact of HIV subtypes and prior raltegravir experience. Antiviral Res 2011;90:164-7
- Bristol-Myers Squibb Co. HIV integrase inhibitors. WO2008154246; 2008
- Bristol-Myers Squibb Co. Bridged heterocycles as HIV integrase inhibitors. WO2009117540; 2009
- Merck & Co., Inc. HIV integrase inhibitors. WO2010042391; 2010
- Merck & Co., Inc. HIV integrase inhibitors. WO2010042392; 2010
- Merck & Co., Inc. Bridged compounds as HIV integrase inhibitors. WO2010088167; 2010
- Merck & Co. Bridged compounds as HIV integrase inhibitors. WO2010088167; 2010
- Serrao E, Odde S, Ramkumar K, Neamati N. Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology 2009;6:25
- Bristol-Myers Squibb Co. HIV integrase inhibitors. WO2011046873; 2011
- Bristol-Myers Squibb Co. Preparation of tetrahydrocarbolines for treatment of HIV infection and AIDS. US20050267105 A1; 2005
- Engelman A, Craigie R. Efficient magnesium-dependent human immunodeficiency virus type 1 integrase activity. J Virol 1995;69:5908-11
- Johnson VA, Byington RT. Infectivity assay. In: Aldovini A, Walker B, editors. Techniques in HIV research. Stockton Press; New York: 1990
- Hare S, Gupta SS, Valkov E, Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010;464:232-7
- Pendri A, Meanwell NA, Peese KM, Walker MA. New first and second generation inhibitors of human immunodeficiency virus-1 integrase. Expert Opin Ther Patents 2011;21:1173-89